Skip to content
lennox

Partner Treatment Library

Longevity, Skin & Wellness

NAD+

A cellular-energy coenzyme discussed for mental clarity, recovery, and healthy-aging goals.

Download evidence brief
Lennox NAD+ product vial
Common goals
Potential short-term support for energy, mental clarity, recovery, and a refreshed sense of wellness.
Best program fit
May fit a clinician-supervised wellness experience paired with sleep, hydration, nutrition, and recovery guidance.
Format
Injectable

Partner education guide

Where this may fit in an offering.

Potential short-term support for energy, mental clarity, recovery, and a refreshed sense of wellness. A direct metabolic-cofactor story that may appeal to individuals focused on healthy aging, resilience, or post-stress recovery. Can anchor a premium, clinician-supervised wellness experience with hydration, rest, sleep, and recovery guidance.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

  • Potential short-term support for energy, mental clarity, recovery, and a refreshed sense of wellness.
  • A direct metabolic-cofactor story that may appeal to individuals focused on healthy aging, resilience, or post-stress recovery.
  • Some individuals report feeling calmer, more alert, or more capable of returning to normal routines after treatment.

Program value

How it may support a program

  • Can anchor a premium, clinician-supervised wellness experience with hydration, rest, sleep, and recovery guidance.
  • Offers an emerging option for individuals interested in cellular-energy and longevity programs.

Potential benefits are based on biologic plausibility, small metabolism studies, clinic experience, and individual reports. Durable clinical outcomes are uncertain and not guaranteed.

02 / Program fit

Program and operational considerations.

01Administration
Catalog format: Injectable. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency
Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration
No randomized study defines a course, maintenance interval, lasting response, or stopping rule for energy, cognition, recovery, addiction, or aging.
04Practical advantages
Can anchor a premium, clinician-supervised wellness experience with hydration, rest, sleep, and recovery guidance.

03 / Suitability considerations

Who may be considered.

Who may be considered

  • A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
  • An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

  • Can anchor a premium, clinician-supervised wellness experience with hydration, rest, sleep, and recovery guidance.
  • Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

01

Common or temporary

  • During IV infusion, nausea, abdominal cramping, diarrhea, sweating, flushing, headache, increased heart rate, and chest pressure are repeatedly described; discomfort may be rate dependent.
  • Injection-site pain, redness, or swelling is possible with non-IV delivery, but reliable frequencies are unavailable.

02

Serious or important

  • Chest symptoms, marked tachycardia, fainting, severe vomiting, electrolyte or volume problems, hypersensitivity, infection, and product-quality events require medical attention.
  • Long-term cardiovascular, liver, kidney, cancer, pregnancy, and interaction safety are not established for repeated high-dose parenteral use.

03

Avoid or use only with specialist input

  • Unstable cardiovascular disease, unexplained chest pain or fainting, pregnancy or breastfeeding, severe uncontrolled illness, or an unverified injectable product.
  • Use that delays evaluation of neurologic symptoms, severe fatigue, substance withdrawal, or another diagnosable condition.

04

Screening checklist

  • Clarify the symptom and target outcome; review cardiovascular history, blood pressure, medications, liver and kidney disease, pregnancy status, hydration, substance use and withdrawal risk, and prior infusion reactions.
  • If research use proceeds, document baseline symptoms and vital signs, use conservative product-specific supervision, and define stop criteria for chest, heart-rate, blood-pressure, or gastrointestinal symptoms.

05

When to refer

  • Chest pain, fainting, new neurologic deficits, severe or persistent vomiting, dangerous withdrawal symptoms, suicidality, or unexplained functional decline requires urgent or specialist care.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Human studies are small and mostly about metabolism or tolerability, not benefit.

01 / Human research

The clearest clinical signal

Small studies describe where infused NAD+ goes and short-term tolerability. They do not prove more energy, clearer thinking, or slower aging.

02 / Real-world reports

What people describe

About 10 detailed injection/infusion accounts were sampled. Some reported brief energy or calm; others reported no benefit. Nausea, cramping, chest pressure, racing heart, faintness, sweating, and injection pain were recurring and sometimes severe.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Nausea, cramping, chest pressure, faster heart rate, faintness, and injection-site reaction. Long-term safety and dose standards are missing. The exact dose, sterility, purity, and label accuracy matter.

Does the research match this exact product?

IV research and clinic data do not establish safety or benefit for an unspecified injectable product.

Research and regulatory context

A 2019 pilot included eight NAD+ infusion participants and focused on metabolism. A 2026 retrospective commercial-clinic pilot found moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during NAD+ infusions and did not establish clinical efficacy.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments